Product Review

Product Update: Menstrual pain relief, Exparel, STI assay, new ART option


 

MENSTRUAL PAIN RELIEF THROUGH MICRO-PULSES

Livia, by iPulse Medical Ltd, is a US Food and Drug Administration (FDA) approved, drug-free option to treat menstrual pain through the transmission of electrical pulses. Electrodes are placed on the body at the source of menstrual pain and send a frequency to the nerves to reduce pain. Livia was designed based on the principles of the “gate control” theory of pain, says iPulse Medical. When the nerves are stimulated by the device’s electrodes, the nerve gate is closed, preventing pain signals from being received or felt in the brain.

The device can be worn in public or at home and allows the user to adjust the frequency of the electrical signal to correspond with her pain intensity. According to iPulse Medical, there are no adverse effects and the user will not build up a tolerance; however, the device should not be worn if the user has a pacemaker or is undergoing fertility treatment.

FOR MORE INFORMATION, VISIT: https://mylivia.com/


EXPAREL FOR CESAREAN DELIVERY

Pacira BioSciences an-nounced completion of their Phase 4 study of Exparel (bupivacaine lipsome injectable suspension), a local analgesic given to patients undergoing planned cesarean delivery (CD), aimed at reducing postsurgical pain and total opioid consumption through the first 72 hours postsurgery. Exparel is administered through transversus abdominis plane field block.

Pacira’s multicenter, randomized, double-blind study of 186 patients showed that those receiving Exparel plus bupivacaine HCl had a 52% reduction in total opioid consumption and significantly lower pain scores through the first 72 hours after CD, compared with those receiving only bupivacaine HCl. The most common adverse effects are itching and nausea. Exparel should not be used for patients under the age of 18 and should be used cautiously in patients with hepatic disease.

FOR MORE INFORMATION, VISIT: https://www.exparel.com/

M GENITALIUM ASSAY DETECTS THE STI

Hologic’s Aptima® Mycoplasma genitalium assay is the first FDA-cleared diagnostic test for this sexually transmitted infection (STI), which has been identified by the Centers for Disease Control and Prevention as an emerging public health threat. The assay is an in vitro nucleic acid amplification test that can be used to verify swab or urine samples from women and men. In published studies, the ribosomal RNA-based assay displayed greater sensitivity than lab-developed or CE-marked DNA-based tests. Early detection is important, Hologic asserts, because M genitalium is increasing in prevalence among higher-risk populations; however, it is not well known and often misdiagnosed, leading to incorrect treatment as well as risk for transmission and recurrence.

Hologic cites several studies that have shown M genitalium can be asymptomatic; however, it also can be associated with nongonococcal urethritis in men and cervicitis in women, as well as increased risk for pelvic inflammatory disease, preterm birth, spontaneous abortion, and infertility. A high percentage of infected people have an antibiotic-resistant strain, demonstrating a need for early detection and screening.

FOR MORE INFORMATION, VISIT: https://www.hologic.com

NEW ART OPTION

INVOcell™ is an intravaginal culture system offering women and their partners another option for proven, effective assisted reproductive technology (ART), says Ferring Pharmaceuticals. The INVOcell Culture Device uses a woman’s own body as a natural incubator during fertilization and early embryo development. It differs from in vitro fertilization, as the incubation happens intravaginally and not in a lab. During the process, the patient undergoes a mild ovarian stimulation and monitoring cycle. After the eggs and sperm are collected, they are placed into the device and then immediately placed into the vaginal cavity to incubate and allow early embryo development to take place. After the incubation period, the INVOcell device is removed and the embryos are transferred or frozen, according to Ferring. For Important Safety Information, see INVOcell’s instructions for use.

FOR MORE INFORMATION, VISIT: https://www.ferringusa.com

Recommended Reading

USPSTF: Screening pregnant women for asymptomatic bacteriuria cuts pyelonephritis risk
MDedge ObGyn
Meeting the obstetrical needs of trans and gender nonconforming patients
MDedge ObGyn
Early maternal anxiety tied to adolescent hyperactivity
MDedge ObGyn
To AROM or not to AROM: Does early amniotomy during induction of labor increase the risk of cesarean delivery?
MDedge ObGyn
High maternal lead levels linked to children’s obesity
MDedge ObGyn